Takeda Pharma denied general conditional reimbursement in Denmark
![Photo: Hannibal Hanschke/Reuters/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14182090.ece/ALTERNATES/schema-16_9/20170616-111859-L-5472x3072ma.jpg)
Takeda Pharma’s insomnia drug Slenyto (melatonin) will not be getting general conditional reimbursement in Denmark, according to a recent decision by the Danish Medicines Agency.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.